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Objectives: The aims of the current study were to assess the association between health-related quality
of life (HRQoL) and treatment satisfaction in a sample of diabetic patients from Palestine, and to
determine the inﬂuence of socio-demographic and clinical factors on HRQoL.
Methods: It was a cross-sectional study performed during the period June 2013 to October 2013. The
Arabic version of Treatment Satisfaction Questionnaire for Medication (TSQM 1.4) was used to assess
treatment satisfaction, and the Arabic version of European Quality of Life scale (EQ-5D-5L) was used to
assess HRQoL. Multiple linear regression was used to estimate which variables were the most important
related to HRQoL.
Results: A total of 385 diabetic patients were included. There were modest positive correlations between
the total score on the Overall Satisfaction domain and EQ-5D-5L (r ¼ 0.14; p ¼ 0.005). After adjusting
multiple covariates by multiple linear regression, the association between the Overall Satisfaction and
HRQoL was not statistically signiﬁcant (p ¼ 0.075); (R ¼ 0.495; adjusted R2 ¼ 0.245; F ¼ 10.3; df ¼ 12;
p < 0.001). The results showed that elderly patients, being unemployed, and number of comorbid
diseases, were signiﬁcantly associated with HRQoL.
Conclusions: Overall, these results indicate that elderly patients, being unemployed, and those with
comorbid diseases, are independent risk factors for poor HRQoL. Furthermore, it emerges that HRQoL and
treatment satisfaction are both probably inﬂuenced by socio-demographic and clinical characteristics. In
fact, to improve diabetic patients’ quality of life, elderly patients were recommended to receive more
attention in their health and economic status.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Type 2 diabetes mellitus (DM) is a common chronic metabolic
disorder causing a signiﬁcant burden of many complications that




Inc. This is an open access article uof patients with DM worldwide is expected to increase from about
170 million in 2000 to about 370 million in 2030 [1]. In addition to
diabetes-related complications, with their substantial impact on
health, life style changes (e.g. physical function, social interaction,
and mental well-being) are considered the most important cause of
impairing health-related quality of life (HRQoL) [2e5].
Treatment satisfaction and HRQoL concepts are commonly used
in clinical and policy research to improve treatment outcomes
related to pharmaceutical care [6,7]. It has been found that higher
patient treatment satisfaction was associated with improving
HRQoL [4,8,9]. In addition, HRQoL refers to self-reported measuresnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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perceptions, experiences, and expectations [10]. Reducing the risk
of hypoglycemia by individualized care may improve glycemic
control by enhancing treatment satisfaction and patients’ quality of
life [11]. Therefore, assessment of the association between treat-
ment satisfaction and HRQoL may help healthcare providers to
recognize the causes that affect quality of life and to identify the
aspects of DM management that needs to be enhanced to improve
treatment outcomes. Although many studies were done to
evaluate of the relationship between HRQoL and treatment satis-
faction [6e8], no study in the Arab world has been conducted to
assess the association between treatment satisfaction and HRQoL
among patients with type 2 DM. The aims of the current study were
to assess the association between treatment satisfaction and HRQoL
in a sample of diabetic patients from Palestine, and to determine
the inﬂuence of socio-demographic and clinical factors on the
quality of life.
Materials and methods
Study design and study area
A cross-sectional descriptive study was carried out between
June 2013 and October 2013. Patients from two outpatient clinics,
Al-Watani Hospital and Al-Makhfyah primary health care clinic,
Nablus, West Bank, Palestine.
Participants and setting
The estimated sample size was 379 patients out of the 25,752
eligible diabetic patients who attend the primary clinic in Nablus
district [12]. Patients were included if they were: (1) 18 years old
and above; (2) diagnosed with type 2 DM; (3) initiated on treat-
ment at least six months before enrollment into the current study;
(4) able to recognize their medications and understand their use;
and (5) agreed to participate in the study.
Data collection instrument
The method was chosen as it was used in previous similar
studies developed by the principle investigators in different pop-
ulations [13e15]. Data collection was done using a structured,
written questionnaire. Four main domains of variables were used:
(1) HRQoL proﬁle of patients with type 2 DM (2) treatment satis-
faction proﬁle of those patients (3) socio-demographic data such as
age, gender, residency (village, city, and Palestinian refugee camps),
occupation (employed or unemployed), marital status (single,
married, divorced, and widowed), income (low, moderate, and
high), educational level (no formal, primary or secondary school,
and university), and height and weight information were provided
by participants with body mass indexes (underweight, normal,
overweight, and obese) calculated later based on this information
by study personnel; and (4) clinical DM related data such as dura-
tion of disease per year (<1, 1e3, 4e5, and >5), type of therapy
(monotheraby versus combination therapy), Insulin use (i.e. yes or
no), total number of chronic co-morbidities (0, 1, 2, 3, 4), and total
number of medications used (1e3, 4e6, and 7) (Table 1). We
developed the data collection form based on several published
studies [2e4,16e18]. The HRQoL in diabetic patients was measured
using the EQ-5D-5L scale. This scale consists of two instruments:
the descriptive EQ-5D-5L system, and the EQ visual analogue scale
(EQ-VAS). The Arabic (national language of Palestine) version of the
EQ-5D was offered by EuroQoL Group. The study was registered
with EuroQoL who granted permission for its conduct. Treatment
satisfaction among diabetic patients was evaluated using the Arabicversion of the Treatment Satisfaction Questionnaire for Medication
(TSQM 1.4), which was permitted for use by Quintiles Strategic
Research Services. This scale is a 14-item, reliable and valid in-
strument providing scores on four domains which are Effectiveness,
Side effects, Convenience, and Overall Satisfaction [7]. The TSQM 1.4
domains were scored and calculated as recommended by the in-
strument’s authors and as explained in previous studies [19,20].
A detailed description is provided in Supplemental Methods and
Materials in Additional ﬁle 1. Data were collected by clinical phar-
macists in face-to-face interviews with the diabetic patients.
A convenience sample of 385 eligible patients with type 2 DM was
included in the ﬁnal analysis. The data collection form was pre-
tested by a pilot sample of 30 patients who were excluded from
the main study and the form was modiﬁed accordingly; the last
modiﬁed version was evaluated by a panel of experts to assess its
content and construct validity.Ethical approval
All study aspects, including patient information use, were
approved by the local institutional review board (IRB) and the local
health authorities before the beginning of this study. Informed
verbal consent from each eligible patient was obtained before
beginning the interviews; however, and the requirement for writ-
ten informed consent was waived.Statistical analysis
The data collected were entered into and analyzed using the
Statistical Package for Social Sciences (SPSS), (SPSS Inc., Chicago, IL,
USA) program version 15. Internal consistency was assessed using
Cronbach’s alpha. Continuous variable was presented as
mean  standard deviation (SD), whereas the categorical variable
was presented as frequency and percentage. Data that are not
normally distributed were expressed as a median with a range of
values (lower-upper quartiles). Data were not normally distributed
and analyzed by the ManneWhitney U test or KruskaleWallis test.
Variables were evaluated if they are normally distributed by the
KolmogoroveSmirnov test. In addition, Spearman’s correlation
coefﬁcient was used to assess if therewas a correlation between the
reported EQ-VAS scores, EQ-5D-5L index values and TSQM scores.
Multiple linear regression was used to estimate which variables
were the most important related to HRQoL (dependent variable).
The independent variables were socio-demographic variables, DM
related clinical variables, and reported TSQM scores. All statistical
tests were performed using a level of signiﬁcance of 0.05.Results
Demographic and diabetes related data
A total of 408 diabetic patients were met, among them 23 pa-
tients were excluded after data collection due to insufﬁcient in-
formation about treatment satisfaction or quality of life. The
patients’ mean age was 59.3  11.2 years, ranging from 19 to 83
years, with 55.1% females. Their mean duration of DM was 12  8.8
years. About 78.4% were married and 60.0% used combination
therapy to control diabetes. The median number of total medica-
tions per day was 5.0 (interquartile range: 4.0e6.0). Table 1
describes the socio-demographic characteristics of the study
population.
Table 1
Socio-demographic and disease-related characteristics of the study patients with differences in health-related quality of life (HRQoL) total scores (N ¼ 385)
Variable Frequency (%)
N ¼ 385
Overall satisfaction score p-Value EQ-5D index score p-Value
Median [interquartile
range]




<38 6 (1.6) 70 [59e79] 69  11.9 0.791a 0.82 [0.72e0.84] 0.78  0.10 0.001a
38e47 52 (13.5) 69 [61e75] 64.5  18.1 0.83 [0.58e1.00] 0.74  0.27
48e57 107 (27.8) 69 [56e69] 62.3  18.3 0.81 [0.68e1.00] 0.79  0.19
58e67 115 (29.9) 69 [53e69] 61.7  22.4 0.75 [0.60e0.85] 0.70  0.24
68e77 87 (22.6) 69 [53e69] 64.5  16.0 0.64 [0.43e0.78] 0.58  0.26
78 18 (4.7) 62 [46e76] 60.2  14.3 0.36 [0.27e0.71] 0.47  0.25
Gender
Male 173 (44.9) 69 [54e69] 64.4  15.9 0.764b 0.80 [0.62e0.88] 0.73  0.25 0.000b
Female 212 (55.1) 69 [53e76] 61.8  20.9 0.69 [0.58e0.85] 0.67  0.25
Smoking status
Non smoker 284 (73.8) 69 [53e76] 63.2  19.7 0.468a 0.72 [0.59e0.85] 0.68  0.26 0.365a
Heavy 8 (2.1) 69 [54e69] 66.3  8.5 0.82 [0.54e0.89] 0.76  0.18
Moderate 56 (14.5) 69 [53e69] 61.1  15.6 0.79 [0.65e0.97] 0.75  0.21
Light 37 (9.6) 69 [58e69] 63.1  19.0 0.80 [0.61e0.94] 0.75  0.21
BMI
Underweight 4 (1.0) 58 [18e92] 55.9  38.7 0.095a 0.61 [0.35e0.94] 0.63  0.31 0.000a
Normal 65 (16.9) 69 [68e76] 66.4  15.8 0.69 [0.50e0.85] 0.66  0.26
Overweight 184 (47.8) 69 [55e69] 65.0  15.1 0.80 [0.66e0.88] 0.73  0.25
Obese 132 (34.3) 69 [53e75] 58.5  23.1 0.68 [0.54e0.83] 0.66  0.25
Residency
Village 174 (45.2) 69 [53e76] 62.1  20.3 0.522a 0.72 [0.60e0.86] 0.69  0.25 0.005a
City 185 (48.0) 69 [61e69] 64.3  17.0 0.79 [0.60e0.88] 0.71  0.26
Palestinian Refugee camps 26 (6.8) 69 [43e71] 58.0  20.6 0.66 [0.45e0.80] 0.60  0.23
Occupation
Employed 105 (27.3) 69 [53e75] 63.4  18 0.887b 0.86 [0.80e1.00] 0.82  0.22 0.000b
Unemployed 280 (72.7) 69 [61e69] 62.8  19.2 0.68 [0.53e0.82] 0.65  0.25
Marital status
Married 302 (78.4) 69 (56e69) 63.1  19.3 0.433b 0.80 [0.63e0.88] 0.72  0.24 0.000b
Single, divorced, widowed 83 (21.6) 69 (53e76) 62.4  17.2 0.64 [0.43e0.80] 0.59  0.25
Income
Moderate to high 156 (40.5) 69 [61e76] 59.7  20.3 0.016b 0.80 [0.64e0.88] 0.74  0.23 0.000b
Low 229 (59.5) 69 [49e69] 65.1  17.5 0.67 [0.50e0.82] 0.63  0.26
Education
No formal 85 (22.1) 69 [53e69] 62.0  14.1 0.157a 0.65 [0.37e0.73] 0.58  0.26 0.000a
Primary or secondary school 235 (61.0) 69 [54e76] 63.1  19.9 0.76 [0.59e0.85] 0.70  0.23
University 65 (16.9) 69 [61e76] 63.4  20.5 0.85 [0.79e1.00] 0.80  0.24
Duration of the disease (years)
<1 8 (2.1) 69 [69e69] 60.7  24.5 0.718a 0.87 [0.81e1.00] 0.86  0.17 0.098a
1e3 64 (16.6) 69 [54e76] 59.8  23.9 0.76 [0.63e0.86] 0.73  0.20
4e5 41 (10.6) 69 [61e76] 66.2  14.8 0.82 [0.77e0.94] 0.78  0.23
>5 272 (70.7) 69 [53e69] 63.2  17.9 0.71 [0.54e0.85] 0.67  0.26
Total number of comorbid diseases
0 58 (15.1) 69 [61e71] 66.9  11.3 0.502a 0.88 [0.72e1.00] 0.83  0.18 0.000a
1 100 (26.0) 69 [60e69] 65.1  15.5 0.80 [0.66e0.85] 0.73  0.23
2 113 (29.4) 69 [54e69] 61.3  22.6 0.77 [0.64e0.88] 0.72  0.24
3 71 (18.4) 69 [53e69] 59.0  19.9 0.63 [0.50e0.81] 0.63  0.22
4 43 (11.2) 69 [48e76] 63.3  20.6 0.59 [0.21e0.71] 0.48  0.30
Therapy type
Mono Therapy 154 (40.0) 69 [54e71] 64.6  16.4 0.669b 0.80 [0.59e0.88] 0.69  0.29 0.231b
Combination therapy 231 (60.0) 69 [53e69] 61.8  20.3 0.71 [0.60e0.85] 0.69  0.22
Insulin use
Yes 201 (52.2) 69 [53e69] 62.1  17.0 0.020b 0.73 [0.54e0.85] 0.67  0.27 0.037b
No 184 (47.8) 69 [61e75] 63.8  20.7 0.79 [0.63e0.87] 0.73  0.23
Total number of diabetic drugs
1 154 (40.0) 69 [54e71] 64.7  16.4 0.010a 0.80 [0.59e0.88] 0.69  0.29 0.377a
2 211 (54.8) 69 [53e69] 61.2  20.1 0.71 [0.66e0.85] 0.70  0.22
3 20 (5.2) 76 [69e83] 68.3  21.7 0.73 [0.47e0.81] 0.65  0.25
Total number of medications
1e3 91 (23.6) 69 [61e69] 65.2  12.1 0.900a 0.85 [0.71e1.00] 0.81  0.20 0.000a
4e6 211 (54.8) 69 [53e69] 62.6  20.3 0.76 [0.59e0.85] 0.68  0.26
7 83 (21.6) 69 [46e76] 61.4  20.8 0.64 [0.44e0.77] 0.59  0.23
BM ¼ body mass index, EQ-5D ¼ European Quality of Life scale, EQ-VAS ¼ European Quality visual analogue scale, NIS ¼ New Israeli Shekel.
a Statistical signiﬁcance of differences calculated using the KruskaleWallis test.
b Statistical signiﬁcance of differences calculated using the ManneWhitney U test.
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The mean satisfaction score was 64.1  15.1 for Effectiveness
domain, 49.4  26.5 for Side Effects domain, 67.6  11.9 forConvenience domain, and 62.9  18.9 for the Overall Satisfaction
domain. Furthermore, the median satisfaction scores in the
Effectiveness, Side Effects, Convenience, and Overall Satisfaction
domains were 66.7 (interquartile range: 61.1e66.7), 50.6
Table 2
Correlation coefﬁcient between treatment satisfaction and HRQoL
Satisfaction domain Spearman’s Rho EQ-5D scorea EQ-VAS scorea
Effectiveness Correlation coefﬁcient 0.091 0.173
Signiﬁcance (2-tailed) 0.076 0.001
Side Effects Correlation coefﬁcient 0.409 0.460
Signiﬁcance (2-tailed) 0.000 0.000
Convenience Correlation coefﬁcient 0.071 0.197
Signiﬁcance (2-tailed) 0.165 0.000
Overall satisfaction Correlation coefﬁcient 0.143 0.193
Signiﬁcance (2-tailed) 0.005 0.000
HRQoL ¼ Health-related quality of life, EQ-5D ¼ European quality of life scale,
EQ-VAS ¼ European quality visual analogue scale.
a Correlation signiﬁcant at the 0.01 level.
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72.2), and 69.4 (interquartile range: 52.8e69.4), respectively. The
results also indicated a signiﬁcant positive correlation between
the Overall Satisfaction score and Effectiveness domain (r ¼ 0.62;
p < 0.001), Side Effects domain (r ¼ 0.29; p ¼ 0.002), and Con-
venience domain (r ¼ 0.41; p < 0.001). The Overall Satisfaction
score was signiﬁcantly associated with total number of diabetic
medications, as well as income and insulin use (p-value <0.05) as
shown in Table 1.
EQ-5D-5L index values and EQ-VAS score
The mean values were 0.7  0.20 for EQ-5D-5L index and
63.7  19.2 for EQ-VAS scores. Furthermore, the median values of
EQ-5D-5L index and EQ-VAS score were 0.76 (interquartile range:
0.59e0.85) and 65 (interquartile range: 50e80), respectively. The
health status reported by the EQ-5D-5L index values was similar to
that reported by EQ-VAS scores, and there was a statistically sig-
niﬁcant positive correlation between EQ-5D score and VAS score
(r ¼ 0.59; p < 0.001). As shown in Table 1, EQ-5D-5L index values
were signiﬁcantly associated with age, BMI, residency, educational
level, total number of medications, and total number of comorbid
diseases (p < 0.05), as well as insulin use, gender, occupation,
marital status, and income (p < 0.05).
Relationship between HRQoL and treatment satisfaction
The Spearman’s correlation coefﬁcient values between the total
scores of Effectiveness, Side Effects, Convenience, and Overall
Satisfaction domains, and the EQ-5D-5L score were 0.09, 0.41, 0.07,
and 0.14, respectively; and for the EQ-VAS scores were 0.17, 0.46,Table 3






Age 0.03 0.01 0.15 2.93 0.004
Gender 0.01 0.03 0.01 0.21 0.836
BMI 0.00 0.02 0.00 0.07 0.943
Residency 0.03 0.02 0.07 1.42 0.157
Occupational status 0.10 0.03 0.18 3.18 0.002
Marital status 0.05 0.03 0.08 1.60 0.110
Income 0.05 0.03 0.09 1.83 0.068
Educational level 0.02 0.01 0.08 1.53 0.126
Number of
chronic diseases
0.03 0.01 0.16 2.68 0.008
Insulin use 0.04 0.02 0.07 1.57 0.116
Number of medications 0.01 0.02 0.04 0.58 0.565
Overall treatment
satisfaction
0.00 0.00 0.08 1.79 0.075
EQ-5D ¼ European quality of life scale; SE ¼ standard error.0.20, and 0.19, respectively (Table 2). Thus, the results of the current
study indicated signiﬁcant modest positive correlations between all
treatment satisfaction domains and EQ-VAS scores, and signiﬁcant
modest positive correlations between Side Effects, Overall
Satisfaction domains, and EQ-5D-5L score (Table 2).
Multiple linear regression analysis has been undertaken in all
cases to control for the potential confounding effects from the pa-
tient socio-demographic and diabetes related data in univariate
analysis. In the current study, only the dependent variable EQ-5D
index score was included in the multiple linear regression model
as there was a statistically signiﬁcant positive correlation between
this score and the EQ-VAS score. As recommended in a previous
study, the independent variables included in multiple linear
regression should not be strongly related to each other, but to the
dependent variable [21]. In our study, because there were inter-
correlations between domains of TSQM, only the Overall satisfac-
tion with treatment domain was the only the independent variable
integrated in the multiple linear regression model, while the other
TSQM domains were excluded (Table 3). After adjusting the mul-
tiple covariates using multiple linear regression, the association
between the Overall Satisfaction and EQ-5D index score was not
statistically signiﬁcant (p¼ 0.075); (R¼ 0.495; adjusted R2¼ 0.245;
F ¼ 10.3; df ¼ 12; p < 0.001). As indicated in Table 3, age,
employment status, and number of comorbid diseases were
signiﬁcantly associated with EQ-5D index score.
Collinearity diagnostics were carried out and evaluated based on
the variance inﬂation factor (VIF) and tolerance. Values of less than
1.87 (VIF) and greater than 1.04 (minimum tolerance) indicated no
multicollinearity problems were found among the independent
variables in the current study.
Discussion
To the best of our knowledge, this study is the ﬁrst of its kind to
address the association between treatment satisfaction and HRQoL
particularly in Palestine and in the Arab diabetic patients in general.
An improved understanding of the risk factors related to HRQoL
has become a key important outcome in DM management plans
[9,22e25]. This type of study may help healthcare providers to
recognize patients’ perceptions about their illness and predict
different dimensions within the diabetic patient’s life.
In the current study, we found that older age, being unem-
ployed, and presence of comorbid diseases were linked to lower
HRQoL. The results of the current study are consistent with those of
Rubin et al. who systematically analyzed the most recent literature
related to DM and quality of life [26]. An Iranian study, conducted
by Javanbakht et al. [3], assessed the relation between DM and
quality of life in a sample of Iranian patients. This Iranian study
found that increased age was related to lower HRQoL. Furthermore,
a Korean study conducted by Lee et al. [17] using EQ-5D found that
age was an important factor determining HRQoL of Korean type 2
diabetic patients. In this Korean study, younger patients (<40 years)
reported to have a better quality of life, most likely due to the short
DM duration and the presence of minor complications. In the cur-
rent study, the duration of DMwas not related to quality of life after
adjustment for other patient socio-demographic and clinical char-
acteristics. These results match those observed in an earlier study
conducted by Redekop et al. [4].
Our results showed that being unemployed was signiﬁcantly
related to lower EQ-5D scores. These ﬁndings are in agreementwith
the previous results reported by Javanbakht and colleagues using
EQ-VAS scores and EQ-5D-5L index values that showed unem-
ployment was associated with a higher possibility to report ‘some
or extreme problems’ in most dimensions of the EQ-5D [3]. Another
study conducted in Malaysia by Cheah et al. [27] that aimed to
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who were unemployed had a signiﬁcantly lower HRQoL compared
to those employed in the private sector. This Malaysian study sug-
gested that unemployed people may have lower income, and this
may clarify its relation with lower HRQoL [27].
An Italian study conducted by Nicolucci et al. [8] aimed to
evaluate the HRQoL and satisfaction to treatment in a large group of
type 2 diabetic patients. The authors reported that diabetic patients’
health perceptions were inﬂuenced not only by underlying socio-
economic status but also by clinical conditions severity. Being un-
employed was associated with signiﬁcantly lower score levels in
each dimension of HRQoL and with treatment satisfaction [8].
Another important ﬁnding was that the presence of comorbid
diseases among diabetic patients was related to lower HRQoL. This
relationship among diabetic patients is well-known and presented
in the literature [3,8,28e30]. In 2007, a study conducted by Papa-
dopoulos et al. [28] that aimed to assess the factors associated with
HRQoL of Greek type 2 DM patients, found that coexistence of non-
diabetic comorbidity, such as hypertension and hyperlipidemia,
generally resulted in lower scale scores. Another study conducted in
Italy by Nicolucci et al. [8] reported that having a number of co-
morbid conditions deteriorates HRQoL among people with DM.
Furthermore, another study conducted in the USA by Wexler and
colleagues [30] to assess the effect of medical comorbidities on
HRQoL in diabetic patients, found that the presence of comorbid
diseases is associated with a signiﬁcantly lower HRQoL.
In the current study, overall, patients reported considerable
levels of HRQoL as well as treatment satisfaction. A low positive
correlation between HRQoL and treatment satisfaction was found
among the study sample. In addition, it is found that treatment
satisfaction was not associated with HRQoL after adjusting others
patient socio-demographic and clinical characteristics. However,
previous studies conducted in different populations such as dia-
betic or hypertensive patients have linked low correlation between
HRQoL and treatment satisfaction [4,14,31]. In our study, the low
correlations between HRQoL and treatment satisfaction seem to be
consistent with a previous study which indicated that HRQoL and
treatment satisfaction are two fairly different phenomena [4].
Previous similar studies reported that patient treatment satisfac-
tion mainly depended on the attitude of physicians toward patients
and the extent of communication between general practitioners
and patients [4,32]. Furthermore, the lack of a correlation between
HRQoL and treatment satisfaction has been documented by another
previous study [33]. In contrast, HRQoL may be linked to treatment
satisfaction due to patients’ beliefs and attitudes towards taking
medications [34]. On the other hand, Diabetes Attitudes, Wishes
and Needs second study (DAWN2) is a large-scale study that
focused on the psychological impact of DM and the suggestion for
best practices to improve diabetic patients’ outcomes [35].
DAWN2 study indicated the need of good resources, training,
education, counseling, and collaboration between health care pro-
viders and diabetic patients [36]. Furthermore, DAWN2 high-
lighted that better outcomes including quality of life were related
with psychosocial support from others [37]. Health care providers
have also recognized the importance of making diabetic patients to
be more actively engaged in self-care and self-management [36].
Strengths and limitations
As a strength point, the current study is considered the ﬁrst
study to assess the association between HRQoL and treatment
satisfaction speciﬁcally in Palestine and among Arab diabetic pa-
tients in general. Another strength of this study is the large sample
size. The large number of diabetic patients included enabled the
study of relatively different associated factors with good statisticalpower. In fact, the current study might even be considered to be
population-based, since most diabetic patients are referred to these
two outpatient clinics [12]. Furthermore, two cross-sectional
studies conducted in Palestine showed a higher rate of DM in a
village community (12.0%) than in a city community (9.8%) at
patients aged between 30 and 65 [38,39]. The rate of reported DM
in our study had higher rate among females and elderly patients at
age 50 years and older. Similar ﬁndings were reported by other
researchers [40e43]. Still, some limitations related to our study
should be documented. First, it is a cross-sectional study design
where the diabetic patients were assessed only once, and it is
therefore difﬁcult to determine the causeeeffect associations be-
tween HRQoL and socio-demographic and clinical characteristics.
Second, the diabetic patients were recruited from one district, and
thus, our conclusions cannot be generalized to the whole diabetic
population in Palestine.
Conclusions
Overall, these results indicate that elderly patients, being un-
employed, and those with comorbid diseases, are independent risk
factors for poor HRQoL. Furthermore, it emerges that HRQoL and
treatment satisfaction are both probably inﬂuenced by socio-
demographic and clinical characteristics. In fact, to improve dia-
betic patients’ quality of life, elderly patients were recommended to
receive more attention in their health and economic status.
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